Description of Medical ServiceVenetoclax is a BCL-2 inhibitor listed on the Australian Register of Therapeutic Goods (ARTG). The TGA-approved indications are as a treatment for:
• Patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) with 17p-del, or
• Patients with relapsed or refractory CLL for whom there are no other suitable treatment options.
Description of Medical ConditionChronic lymphoid leukaemia (CLL), which is also known as B-cell Chronic lymphoid leukaemia (B-CLL), is a specific type of leukaemia, a group of cancers usually originated in bone marrow and resulting in abnormally high numbers of white blood cells. The presence of a 17p deletion is associated with a significantly poorer prognosis, and patients harbouring a 17p deletion show marked resistance to genotoxic chemotherapies recommended as first-line treatment for CLL.
Reason for ApplicationAmendment to MBS item
Medical Service TypeCo-dependent technology
Previous Application NumberNot Applicable
Public Summary DocumentPublic Summary Document - updated (PDF 867 KB)
Public Summary Document - updated (Word 79 KB)
Meetings for this Application
ESC8 June 2017
MSAC6 - 7 April 2017
27 July 2017
22-23 November 2018